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Abstract 
 
A series of bicyclic peptides have been designed and synthesized to provide ammonium 
ion complexation sites via hydrogen bonding in a tetrahedral geometry.  Molecular 
modeling dynamics and electrostatics studies indicate that target compounds 1d-6d may 
provide better selectivity for ammonium ions over potassium ions than the ammonium 
ionophore currently used for blood analysis applications, nonactin.  Attempts to 
synthesize 1d, cyclo(L-Glu1—D-Val2—L-Ala3—D-Lys4—D-Val5—L-Val6)-cyclo-(1γ-
4ε), were unsuccessful due to poor solubility of the synthetic intermediates.  This led to 
the design of 2d-6d in which specific amino acid residues were chosen to provide higher 
solubility.  Compound 2d, cyclo(L-Glu1—D-Ala2—D-Ala3—L-Lys4—D-Ala5—L-Ala6)-
cyclo-(1γ-4ε), was successfully synthesized, but was also too insoluble for 
characterization or testing in an ion selective electrode (ISE) sensor format.  Compound 
6d, cyclo(L-Glu1—D-Leu2—Aib3—L-Lys4—D-Leu5—D-Ala6)-cyclo-(1γ-4ε), was 
successfully synthesized and characterized.  When 6d was incorporated into an ISE 
sensor and tested as an ammonium ionophore, results indicated that the bicyclic peptide 
lacked solubility in the ISE membrane.  A 13C-NMR study has been initiated in order to 
evaluate selectivity of 6d for ammonium over potassium and sodium cations in solution.  
Preliminary results with the potassium ionophore valinomycin as a control have been 
completed. 
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1 Introduction 
 
The levels of urea and creatinine in blood are important diagnostic indicators of renal, 
thyroid, and muscle function.1 Significant effort has been expended in developing reliable 
sensors for the detection of these analytes.  At the present time, urea and creatinine levels 
are measured indirectly following enzyme-catalyzed hydrolysis to produce ammonium 
ions.  Typically, measurement of ammonium ion concentrations is achieved by carrier-
based ion selective electrodes (ISEs) containing the natural antibiotic nonactin as an 
ionophore.2 In ISEs, a highly viscous liquid membrane (such as plasticized PVC) lies 
between the aqueous sample containing the ion and an internal electrolyte solution.  The 
membrane is doped with a selective ion carrier (nonactin in the case of ammonium) and a 
lipophilic salt that acts as an ion exchanger.  The potential that develops at the 
membrane/sample interface is proportional to the activity (concentration) of ammonium 
ions in the aqueous sample.3 
 
The two key properties of any ion sensor are sensitivity to the desired ion in the required 
concentration range and selectivity for one specific ion over all other interfering ions, 
properties that are primarily imparted by the ionophore.  As an ammonium ionophore, 
nonactin, shown in Figure 1, forms four hydrogen bonds from its ethereal oxygens to the 
ammonium ion.4  Nonactin-based ISEs show reasonable selectivity for ammonium over 
sodium ions (log ++ NaNHK ,4 = -2.4)
4, but only modest selectivity over potassium ions (log 
++ KNHK ,4 = -1.0)
4.  For this reason, much effort has focused on the development of new 
 2 
ammonium ionophores, particularly with increased selectivity over potassium ions to 
improve accuracy of ammonium ion determinations in the presence of potassium ions.4   
 
In designing ammonium ionophores, there are three main factors to consider.  The first is 
size-fit requirements.  A rigid framework with a cavity appropriately sized for 
ammonium ion (ionic radius 1.43 Å)5 is necessary to impart high selectivity over 
interfering cations of other sizes.6,7  If the substrate is too flexible, it can change 
conformations to allow coordination with larger and smaller cations besides the desired 
ion.  In addition, complexation is thermodynamically more favorable when the ionophore 
is conformationally preorganized into the correct binding geometry in order to minimize 
the entropic cost of cation binding.3  Secondly, the ammonium ionophore should exhibit a 
spatial distribution of lone-pair electrons for effective hydrogen bonding with the 
tetrahedral ammonium ion.6  Interfering potassium ions are of similar size (1.33 Å)5 to 
ammonium ions, but have spherical symmetry and therefore prefer ionic bonds with 
coordination numbers of six or higher.2  For this reason, the coordination geometry is 
responsible for imparting selectivity for ammonium over potassium ions.  Lastly, the 
Figure 1:  Nonactin, the current industry standard ammonium ionophore 
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ionophore should be highly lipophilic6 in order to be compatible with the nonpolar 
membrane environment8 of ion selective electrodes and to prevent extraction of the 
ionophore from the sensor during testing.3  
  
One of the earliest ammonium ionophores exhibiting some of these design elements was 
the spherical macrotricyclic cryptand reported by Lehn et al.5 (shown in Figure 2).  This 
compound exhibited extremely high ammonium over potassium ion selectivity (250 times 
higher than nonactin) as determined by NMR studies and formed highly stable 
ammonium complexes (105 times higher than nonactin) as calculated by pH metric 
titration to determine stability constants in aqueous solution.  The high selectivity over 
potassium ion has been attributed to the tetrahedral binding site geometry that favors 
complexation of the tetrahedral ammonium ion over that of the spherically symmetrical 
potassium ion.  In addition, the macrocyclic nature of the cryptand provides the rigidity 
necessary to prevent complexation of larger and smaller interfering cations.  However, 
the cryptand is too basic (it exists in its conjugate acid form near neutral blood pH) and 
hydrophilic (it would leach from the membrane into the aqueous phase during sensor 
operation) for use as an ionophore in an ISE sensor format.2  In addition, this system 
exhibits a very low dissociation constant indicating very slow cation exchange.  For this 
reason, the cryptand is effectively an ammonium ion sink, whereas an ISE sensor 
application requires reversible ion binding.8  
 4 
 
 
 
Chin et al. reported a rationally designed ammonium receptor, 1,3,5-tris(3,5-
dimethylpyrazol-1-ylmethyl)-2,4,6-triethyl benzene (shown in Figure 3).2  This 
ionophore was designed to have the lone pair electrons on the imine nitrogens 
preorganized into the correct geometry for binding ammonium ions through hydrogen 
bonds.  The ethyl and methyl groups provide steric interactions to force the receptor into 
the desired geometry and to block the ligands from binding potassium ions.  This 
ionophore was highly selective (log ++ KNHK ,4 = -2.6 (nonactin –1.0)
4, log ++ NaNHK ,4 = -2.8 
(nonactin –2.6)4) in an ISE sensor format.  However, the ammonium detection limit was 
10-4 M (100 times higher than nonactin) and therefore the sensor was not sufficiently 
sensitive.9  A sensor for blood analysis applications must exhibit sufficient sensitivity to 
detect lower limits of normal urea and creatinine blood concentrations, which are 1 x 10-3 
M and 5 x 10-5 M respectively.10 
Figure 2:  Lehn’s macrotricyclic cryptand 
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Suzuki et al. have synthesized an ammonium ionophore based on a 19-membered crown 
ether containing three decalino subunits (shown in Figure 4).6  The decalino subunits add 
rigidity to prevent folding of the receptor to coordinate smaller cations, add bulkiness to 
block larger interfering cations from entering the cavity, and also increase the 
lipophilicity of the ionophore.  In an ISE sensor format, this ionophore exhibited similar 
ammonium over potassium ion selectivity  (log ++ KNHK ,4 = -1.00 (nonactin –1.0)
4) and 
increased ammonium over sodium ion selectivity  (log ++ NaNHK ,4 = -3.52 (nonactin –2.6)
4) 
compared to nonactin and a nearly Nernstian response (58.1 mV/decade) in the activity 
range 5 x 10-6 – 10-1 M ammonium ion.  The observation of Nernstian behavior is 
particularly important.  The relation between the potential difference across the sensor 
membrane and the activity of ammonium ion should follow the well-known Nernst 
equation (Equation 1): 
E = E° - (2.303RT/nF) log a   (1) 
Figure 3:  1,3,5-tris(3,5-dimethylpyrazol-1-ylmethyl)-2,4,6-triethyl 
benzene ammonium ionophore 
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Here, E is the electromotive force (emf) of the cell in volts, E° is the emf cell constant, F 
is the Faraday constant, a is the activity of the analyte, n is the charge of the measured 
species, R is the gas constant, and T is the temperature.  This equation is in the form of y 
= mx + b and therefore a plot of E versus log a will give a straight line with a slope of 
2.303RT/nF.  For the measurement of monovalent cations at 25°C, n = 1 and the slope 
becomes 59.16 mV/dec.  Thus an ISE that measures ammonium ion and operates 
according to the Nernst equation should exhibit a slope of 59.16 mV/dec. 
 
 
 
Nam et al. have reported a thiazole containing dibenzo-18-crown-6 derivative (shown in 
Figure 5) as an ammonium ionophore in an ISE sensor format.9  This design is primarily 
based on size-fit factors.  The aromatic units increase rigidity and the thiazoles provide 
hydrogen bonding sites.  This ionophore exhibited high selectivity (log ++ KNHK ,4 = -1.3 
(nonactin –1.0)4, log ++ NaNHK ,4 = -3.9 (nonactin –2.6)
4) and a similar detection limit of ~3 
x 10-6 M compared to nonactin (10-6 M)6 in an ISE sensor format.   
Figure 4:  19-crown-6 ether with decalino subunits 
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Kim et al. designed and synthesized an ammonium receptor based on both hydrogen 
bonding and cation-π interactions, consisting of two benzene rings held rigidly together 
by three benzocrown ether units as shown in Figure 6.6  This ionophore design involves a 
rigid cavity of the appropriate size containing a spatial distribution of ether lone pair 
electrons for tetrahedral coordination to ammonium along with cation-π interactions 
provided by the top and bottom benzene rings.  Compared to nonactin-based sensors, 
ISEs doped with this ionophore exhibited similar selectivity (log ++ KNHK ,4 = -0.97 
(nonactin –1.0)4, log ++ NaNHK ,4 = -3.00 (nonactin –2.6)
4) and a similar detection limit of 
3.2 x 10-6 M (nonactin (10-6 M)6). 
Figure 5:  Dibenzo-18-crown-6 ether with thiazole subunits 
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McGimpsey et al. have designed and synthesized an ammonium ionophore for an ISE 
based on a cyclic depsipeptide structure.8  The design of this ionophore was inspired by 
valinomycin, the naturally occurring antibiotic having a high selectivity for potassium 
ions.  Valinomycin, a cyclic depsipeptide consisting of alternating amide and ester 
linkages (12 total) (shown in Figure 7a), preorganizes through hydrogen bonding of its 
amide carbonyl groups to form a pocket with its six ester carbonyl oxygens available for 
electrostatic stabilization of potassium ions through octahedral-type complexation.11  The 
new ionophore (shown in Figure 7b) consists of alternating amide and ester units (6 
total), which is effectively half of a valinomycin molecule.  Unlike valinomycin, this 
depsipeptide is too rigid to fold upon itself and therefore provides a cavity appropriately 
sized for ammonium ions, which provides the tetrahedral complexation geometry 
required for ammonium ion binding, but not the octahedral binding geometry required by 
potassium ions.  ISE sensors incorporating this ionophore exhibited similar selectivity for 
ammonium over potassium and sodium ions compared to nonactin-based sensors (log 
Figure 6:  Two benzene rings held together by three benzocrown ether units 
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++ KNHK ,4 = -0.6 (nonactin –1.0)
4, log ++ NaNHK ,4 = -2.1 (nonactin –2.4)
4) and a nearly 
Nernstian response (60.1 mV/decade at 37˚C).   
 
 
Cyclic peptides are known to bind and transport metal cations in biological systems.12  
Their ease of synthesis and potential for flexible sequence modification make them good 
candidates for new ionophores.13  However, ordinary cyclic peptides are too flexible to 
bind substrates in a well-defined cavity14, leading to low selectivity as sensor 
components.  The addition of a second ring in bicyclic peptides should increase cation 
binding selectivity by increasing rigidity.  Andreu et al. have synthesized cyclo(1,5-ε-
succinoyl) (Lys-Gly-Gly-Gly)2 (shown in Figure 8a) which exhibits a slight preference 
for binding Sr2+ over other cations.13  Zanotti et al. have reported synthesis, 
conformation, and calcium-binding studies for the bicyclic nonapeptides cyclo(Glu1-X2-
Figure 7:  (a) Valinomycin  (b) new depsipeptide ammonium ionophore 
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Pro3-Gly4-Lys5-X6-Pro7-Gly8)-cyclo-(1γ → 5ε) Gly9, where X = Ala or Leu (shown in 
Figure 8b).15,16  
 
 
 
Our research has been directed toward the synthesis and evaluation of new bicyclic 
peptide ammonium ionophores with predicted ammonium over potassium ion selectivity 
greater than the industry standard nonactin in an ISE sensor format in order to improve 
the accuracy of ammonium ion determinations in the presence of potassium ions for 
clinical evaluation of urea and creatinine levels.  The ease of synthesis and demonstrated 
cation-binding ability make bicyclic peptides promising candidates.  Molecular modeling 
suggests the target compounds 1d, 2d, 3d, 4d, 5d, and 6d shown in Figure 9 should 
exhibit tetrahedral coordination geometry in a cavity appropriately sized for ammonium 
ions.   
 
 
 
 
 
 
 
 
Figure 8:  (a) cyclo(1,5- ε-succinoyl) (Lys-Gly-Gly-Gly)2  (b) cyclo(Glu1-X2-
Pro3-Gly4-Lys5-X6-Pro7-Gly8)-cyclo-(1γ → 5ε) Gly9, where X = Ala or  Leu 
Gly Gly Gly
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The naming system for these compounds is based on their preparation from three 
important synthetic precursors, as shown in Figure 10 for target 1d (applicable to all 
target compounds). 
 
 
Figure 9:  Target bicyclic peptide ammonium ionophores 
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Figure 10:  General synthetic scheme for target compound 1d 
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2 Experimental 
 
 
2.1 General Methods and Materials 
 
Mass spectra were performed by Synpep Corp. (Dublin, CA) and Bayer Diagnostics 
Analytical Department (Medfield, MA).  1H and 13C-NMR were recorded on a Bruker 
Avance 400.  All Fmoc-protected amino acids, all Wang resins, benzotriazole-1-yl-oxy-
tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), and 1-hydroxybenzo-
triazole hydrate (HOBT) were purchased from Calbiochem-Novabiochem Corp.  All 
solvents and reagents were analytical reagent grade, purchased from local suppliers, and 
used as received without further purification.  Buffers were prepared with deionized 
water (18 MΩ·cm). 
 
2.2 Molecular Modeling Calculations 
 
Molecular modeling was performed on an SGI 320 running Windows NT, as previously 
reported.8  Calculations were carried out using the Molecular Operating Environment 
version 2000.02 computing package (Chemical Computing Group Inc., Montreal, PQ, 
Canada).  Structures were minimized first using the AMBER94 potential control under a 
solvent dielectric of 5.  PEF95SAC was used to calculate partial charges.  Minimized 
structures were then subjected to a 30-ps molecular dynamics simulation employing the 
NVT statistical ensemble.  The structures were heated to 400 K, equilibrated at 310 K, 
and cooled to 290 K in the dynamics thermal cycle at a rate of 10 K/ps.  The lowest 
energy structures obtained from these dynamics calculations were then minimized again.  
 14 
Using the minimized structures, docking energies of the ammonium and the potassium 
cations were calculated by employing the default parameters supplied with the program. 
 
2.3 Synthesis 
 
The synthetic scheme for target compound 1d is shown in Scheme 1. 
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Scheme 1:  Synthesis of 1d 
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2.3.1  Synthesis of 1a 
 
Solid phase peptide synthesis was carried out on 5 g of Fmoc-Ala-Wang resin (0.41 
mmol/g loading).  The resin was swelled by adding 30 mL DMF and mixing with N2 for 
30 min., at which point the DMF was removed by aspiration.  The resin-bound N-Fmoc 
protected alanine was deprotected with 20% piperidine in DMF (30 mL, 10 min.).  The 
solution was removed by aspiration and the resin was washed 3x with 30 mL DMF, 3x 
with 30 mL MeOH, 1x with 30 mL EtOH, and vacuum dried.  A Kaiser test was 
performed by adding 2 drops of each of three solutions to a few resin beads and heating 
in the oven for 3-4 min.  The solutions were prepared by dissolving 5 g of ninhydrin in 
100 mL EtOH, dissolving 80 g of phenol in 20 mL EtOH, and adding 2 mL of a 0.001 M 
aqueous solution of potassium cyanide to 98 mL pyridine.17  A positive Kaiser test for 
free amine, as indicated by blue beads, confirmed successful deprotection.  The resin was 
reswelled in 30 mL of DMF mixed with N2 for 10 min.  2.60 g (2.5 eq) Fmoc-D-Lys(Z), 
2.67 g (2.5 eq) PyBOP, 0.69 g (2.5 eq) HOBT, and 1.8 mL (5 eq) diisopropylethylamine 
(DIPEA) were dissolved in 5 mL DMF and added to the prepared resin.  The total 
volume was increased to 30 mL and mixed with N2 for 4 hr. at which time the solution 
was removed by aspiration and the resin was rinsed 3x with DMF, 3x with MeOH, 1x 
with EtOH, and vacuum dried.  A negative Kaiser test confirmed complete coupling.  
This [deprotection - rinses - Kaiser test - coupling reaction - rinses - Kaiser test] cycle 
was repeated for the remaining four amino acid residues to give (Resin)—(L-Ala)—(D-
Lys(Z))—(D-Val)—(L-Val)—(L-Glu(OBzl))—(D-Val-Fmoc).  In the event of 
incomplete coupling, as indicated by a positive Kaiser test, the coupling reaction was 
repeated.  The terminal valine residue was deprotected and a Kaiser test was performed to 
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confirm successful deprotection.  The resin was rinsed 3x with DMF, 3x with MeOH, 2x 
with DMF, 2x with MeOH, and vacuum dried.  
 
The linear peptide was cleaved from the resin with 30 mL of TFA/H20/triisopropylsilane 
(TIS) 95/2.5/2.5 over 2.5 hr. by mixing with N2.  The peptide solution was removed by 
aspiration and concentrated down to a few mL’s.  Cold ether precipitated the linear 
peptide as a white solid, which was collected by filtration.  The peptide was dissolved in 
MeOH and reprecipitated twice to obtain 1.2 g (67% yield) of a white powder.  1H and 
13C-NMR and ESI MS of this and subsequent compounds may be found in Appendix A.  
1H-NMR (400 MHz, DMSO), δ 0.64-1.02 (m, 18H), 1.13-1.68 (m, 9H), 1.75-2.15 (m, 
5H), 2.28-2.51 (m, 2H), 2.88-3.02 (m, 2H), 4.10-4.56 (m, 7H), 5.00 (s, 2H), 5.08 (s, 2H), 
7.17-7.51 (m, 12H), 7.65-8.18 (m, 7H), 8.42 (d, J = 7.8 Hz, 1H);  13C-NMR (100 MHz, 
DMSO), δ 17.7, 17.9, 18.2, 18.2, 18.7, 18.9, 19.7 (CH3), 22.9, 28.1, 29.4 (CH2), 30.3 
(CH), 30.4 (CH2), 30.8, 31.1 (CH), 32.2, 40.5 (CH2), 47.8, 52.2, 52.7, 57.7, 57.7, 58.2  
(CH), 65.5, 65.9 (CH2), 128.1, 128.3, 128.4, 128.7, 128.8 (CH, Ar), 136.5, 137.6 (C, Ar), 
156.4, 168.5, 170.9, 171.0, 171.1, 171.4, 172.3, 174.3 (C=O). ESI MS m/z (%) calcd. for 
C44H66N7O11 (M+H+) 868.5 found 868.2 (100). 
 
2.3.2  Synthesis of 1b 
 
The 1.20 g (1.38 mmol) of linear peptide 1a was dissolved in approximately 450 mL 
DMF and 50 mL benzene.  0.682 g (1.3 eq) O-(7-Azabenzotriazole-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HATU), 0.244 g (1.3 eq) 1-Hydroxy-7-
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azabenzotriazole (HOAT), and 2.4 mL (10 eq) DIPEA dissolved in 5 mL of DMF was 
added and the solution was stirred for 24 hr. at room temperature.  At this point, the DMF 
was removed in vacuo, 55-60 ˚C.  The residue was dissolved in DCM and extracted 3x 
with 100 mL of saturated NaHCO3, 3x with 100 mL of 10% citric acid, and dried over 
Na2SO4.  The organic solution was concentrated completely, and then dissolved in 
MeOH.  The peptide was precipitated with ether/hexanes at –4 ˚C and collected by 
filtration to give 170 mg (14% yield) of crude monocyclized peptide.  Characterization by 
1H and 13C-NMR and ESI MS was inconclusive.   
 
2.3.3  Synthesis of 1c 
 
The 170 mg (0.200 mmol) of 1b was combined with 30 mg from a previous synthesis and 
dissolved in 100 mL of MeOH.  The benzyl protecting groups on the glutamic acid and 
lysine side chains were removed by using 0.2 g of Pd activated carbon (10 wt%), and H2 
at atmospheric pressure while stirring the solution for 3 hr.  The spent catalyst was 
removed by filtration and the solution was concentrated totally in vacuo, 40 ˚C.  1H and 
13C-NMR spectra in DMSO confirmed loss of benzyl groups.  The 120 mg (96% yield) of 
peptide was used without further purification or characterization.   
 
2.3.4  Synthesis of 1d 
 
The 120 mg (0.192 mmol) of 1c was stirred in 15 mL thionyl chloride for 1.5 hr. at which 
point the thionyl chloride was removed in vacuo.  The residue was dissolved in benzene, 
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and then concentrated completely to remove residual thionyl chloride.  The peptide acid 
chloride was dissolved in 30 mL DCM, to which 0.27 mL (10 eq) triethylamine (TEA) 
was added and the solution was stirred for 18 hr. at which point, the solution was 
concentrated completely, then redissolved in 5% MeOH/DCM.  The addition of cold 
ether precipitated 20 mg of a brown solid which was collected by filtration.  
Characterization by ESI MS was inconclusive.   
 
2.3.5  Synthesis of 2a 
 
Solid phase synthesis was carried out on 5.035 g of Fmoc-Ala-Wang resin (0.41 mmol/g 
loading) for the amino acid sequence (L-Ala)—(L-Lys(Z))—(D-Ala)—(D-Ala)—(L-
Glu(OBzl))—(D-Ala) using the same general solid phase methods described for 
compound 1a.   
 
The linear peptide was cleaved from the resin with 30 mL of TFA/H20/TIS 95/2.5/2.5 
mixed with N2 for 2.5 hr.  The peptide solution was removed by aspiration and 
concentrated down to a few mL’s.  Cold ether precipitated the linear peptide as a white 
solid, which was collected by filtration.  The peptide was dissolved in MeOH, 
precipitated with cold ether, and filtered to obtain 1.24 g (77% yield) of a white powder.  
Rf(RP) .35 (1.9:1 H2O/MeCN);  1H-NMR (400 MHz, DMSO), δ 0.90-1.33 (m, 21H), 
1.35-1.49 (m, 1H), 1.53-1.77 (m, 2H), 2.05-2.31 (m, 4H), 2.62-2.77 (m, 2H), 3.10-3.26 
(m, 1H), 3.53-3.66 (m, 1H), 3.75-4.14 (m, 7H), 4.76 (s, 2H), 4.85 (s, 2H), 7.00 (t, J = 5.6 
Hz, 1H), 7.03-7.22 (m, 10H, Ar), 7.67 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 7.1 Hz, 1H), 7.83 
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(d, J = 7.1 Hz, 1H), 8.19 (d, J = 7.3 Hz, 1H), 8.59 (d, J = 8.1 Hz, 1H);  13C-NMR (100 
MHz, DMSO), δ 17.9, 17.9, 18.4, 18.4 (CH3), 22.8, 27.7, 29.4, 30.2, 32.0, 40.5 (CH2), 
48.4, 48.6, 48.6, 48.8, 52.1, 52.4 (CH), 65.5, 66.0 (CH2), 128.1, 128.3, 128.4, 128.7, 
128.8 (CH, Ar), 136.4, 137.6 (C, Ar), 156.4, 170.4, 170.8, 171.6, 172.1, 172.3, 172.3, 
174.7 (C=O).  ESI MS m/z (%) calcd. for C38H54N7O11 (M+H+) 784.4 found 784.0 (100). 
 
2.3.6  Synthesis of 2b 
 
1.26 g (1.61 mmol) of 2a was dissolved in 600 mL of DMF and stirred at 0 ˚C.  0.791 g 
(1.3 eq) HATU, 0.283 g (1.3 eq) HOAT, and 2.8 mL (10 eq) DIPEA dissolved in 5 mL of 
DMF was added and the reaction mixture was stirred for 4 hr., at which point the DMF 
was removed in vacuo, 55-60 ˚C.  The residue was dissolved in MeOH and cold ether 
was added to precipitate a white solid, which was collected by filtration and redissolved 
in MeOH.  A white solid that precipitated out of the MeOH solution was removed by 
filtration.  The solution was concentrated completely and purified by reverse phase (C18) 
column chromatography (1.2:1 H2O:MeCN) to obtain 250 mg (20% yield) of a white 
solid.   Rf(RP) .31 (1.2:1 H2O/MeCN);  1H-NMR (400 MHz, MeOD), δ 1.50-1.82 (m, 
18H), 1.91-2.14 (m, 2H), 2.17-2.37 (m, 2H), 2.64-2.79 (m, 2H), 3.31-3.44 (m, 2H), 4.28-
4.33 (m, 1H), 4.38-4.44 (m, 1H), 4.51-4.61 (m, 2H), 4.68-4.80 (m, 2H), 5.31 (s, 2H), 5.37 
(s, 2H), 7.47-7.71 (m, 10H, Ar);  13C-NMR (100 MHz, MeOD), δ 17.4, 17.9, 18.1, 19.2 
(CH3), 24.4, 27.6, 30.9, 31.5, 32.2, 41.6 (CH2), 50.0, 50.7, 51.0, 52.0, 55.0, 56.7 (CH), 
67.8, 67.9 (CH2), 129.2, 129.4, 129.6, 129.7, 129.9, 130.0 (CH, Ar), 137.9, 138.8 (C, Ar), 
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159.4, 174.3, 174.6, 174.6, 174.8, 174.8, 174.9, 175.9 (C=O). ESI MS m/z (%) calcd. for 
C38H52N7O10 (M+H+) 766.4 found 766.3 (6), calcd. M+Na+ 788.4 found 788.3 (100). 
 
2.3.7  Synthesis of 2c 
 
250 mg of 2b was combined with 120 mg from a previous synthesis for a total of 370 mg 
(0.483 mmol) and dissolved in 50 mL of MeOH.  The benzyl protecting groups on the 
glutamic acid and lysine side chains were removed by using 0.2 g of Pd activated carbon 
(10 wt%), and H2 at atmospheric pressure while stirring the solution for 3.5 hr.  The spent 
catalyst was removed by filtration and the solution was concentrated completely.  
Analytical TLC with ninhydrin tests showed a product mixture and therefore the 
hydrogenation reaction was repeated for 3.5 hr.  The product was 160 mg (61% yield) of 
a white solid.  Essentially complete loss of benzyl protecting groups was confirmed by 1H 
and 13C-NMR.  The peptide was used without further purification or characterization.   
 
2.3.8  Synthesis of 2d 
 
160 mg (0.295 mmol) of 2c was dissolved in 125 mL of DMF and stirred at 0 ˚C.  0.146 
(1.3 eq) HATU, 0.052 g (1.3 eq) HOAT, and 0.52 mL (10 eq) DIPEA dissolved in 5 mL 
of DMF was added and the reaction mixture was stirred for 4 hr., at which point the DMF 
was removed in vacuo, 45˚C.  The residue was dissolved in MeOH and a white 
suspension was removed by centrifugation.  The solution was concentrated completely 
and extracted 3x with DCM/H20.  The aqueous portion was vacuum evaporated and 
 23 
dissolved in 1:1:3 MeOH:EtOAc:DCM.  The insoluble portion was removed by filtration.  
Again, the solution was concentrated completely, dissolved in MeOH, reprecipitated with 
cold ether, and collected by centrifugation 4x to obtain 45 mg (29% yield) of a yellow 
solid.  This was redissolved in 50 mL of MeOH, cooled to 5 ˚C for 4 hr., and centrifuged 
to collect 10 mg of an insoluble white precipitate.  ESI MS m/z (%) calcd. for 
C23H37N7O7Na (M+Na+) 546.3 found 546.3 (25) in the partially purified product (prior to 
the final precipitation from MeOH).      
 
2.3.9  Synthesis of 3a 
 
Solid phase synthesis was carried out on Wang resin (1.1 mmol/g loading) for the amino 
acid sequence (L-MeAla)—(L-Lys(Z))—(D-Ala)—(D-MeAla)—(L-Glu(OBzl))—(D-
Ala).  2.803 g Wang resin was swelled in 30 mL DMF mixed with N2 for 30 min. at 
which point the DMF was removed by aspiration.  3.006 g (3 eq) of Fmoc-MeAla was 
dissolved in 50 mL of dry DCM and stirred at 0 ˚C.  1.45 mL diisopropylcarbodiimide 
(DIPCDI) in 5 mL of DMF was added and the reaction mixture was stirred for 30 min. At 
this point, the solution was concentrated completely, dissolved in 5 mL DMF, and added 
to the resin.  0.038 g (0.1 eq) dimethylaminopyridine (DMAP) in DMF was added to the 
resin and the total volume was increased to 40 mL.  The solution was mixed with N2 for 
1.5 hr. covered at room temperature.  Loading of the first amino acid to the resin was 
evaluated by cleaving the Fmoc protection group from a known mass of resin (20 mg) in 
a 100 mL solution of 20% piperidine in DMF and monitoring the UV absorption at 290 
nm.  Using a molar extinction coefficient of 4950 a loading of 72% was obtained.  
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Stepwise addition of the next 5 amino acids was carried out according to the standard 
solid phase method described for compound 1a.  The Kaiser test was inconclusive for 
secondary amines, so completeness of reaction was monitored by UV absorption of Fmoc 
when coupling to resin-bound terminal MeAla residues.  In addition, deprotection 
reactions were allowed longer reaction time (15-20 min.) and repeated.   
 
The linear peptide was cleaved from the resin with 30 mL of TFA/H20/TIS 95/2.5/2.5 
over 2.5 hr. by mixing with N2.  The peptide solution was removed by aspiration and 
concentrated completely to yield an oil.  ESI MS indicated that none of the desired 
product was formed.   
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The general scheme for synthesis of the intermediates 4a and 4b of target compound 4d 
is shown in Scheme 2. 
 
Scheme 2:  Synthesis of 4a and 4b 
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2)  DMAP, DMF, 70 min
1)  DIPCDI, DCM, 30 min
Solid Phase Peptide Synthesis
CHCl3-AcOH-NMM
 Pd (PPh3)4  PyBOP, HOBT, DIPEA, 18.5 hr
+ O
O
NH
Fmoc
OOResin
O
O
NH
Fmoc
OOH
O
O
NH
OOResin
NH
NH
NH
NH
NH2
O
O
O
O
O
(H2C)4
NH
O O Ph
3)  Ac2O, pyridine, DMF, 30 min
OH
O
NH
OOResin
NH
NH
NH
NH
NH2
O
O
O
O
O
(H2C)4
NH
O O Ph
O
NH
O
OResin
N
H
NH
NH
N
H
NH
O
O
O
O
O
(CH2)4
NH
O
O
Ph
 TFA, TIS, H20, 2.5 hr
4a
DMF
 26 
 
2.3.10  Synthesis of 4a 
 
Solid phase synthesis was carried out on Wang resin (1.0 mmol/g loading) for the amino 
acid sequence (L-Glu-OAll)—(D-Ala)—(Aib)—(L-Lys(Z))—(Aib)—(D-Leu).  2.013 g 
Wang resin was swelled in 30 mL DMF mixed with N2 for 30 min. at which point the 
DMF was removed by aspiration.  2.059 g (2.5 eq) of Fmoc-Glu-OAll was dissolved in 
50 mL of dry DCM and stirred at 0 ˚C.  0.79 mL DIPCDI in 5 mL of DMF was added 
and the reaction mixture was stirred for 30 min., at which point the solution was 
concentrated completely, dissolved in 5 mL DMF, and added to the resin.  0.025 g (0.1 
eq) DMAP in DMF was added to the resin and the total volume was increased to 40 mL.  
The solution was mixed with N2 for 70 min. at room temperature.  Loading of the first 
amino acid to the resin was evaluated by cleaving the Fmoc protecting group from a 
known mass of resin (20 mg) in a 100 mL solution of 20% piperidine in DMF and 
monitoring the UV absorption at 290 nm.  Using a molar extinction coefficient of 4950 a 
loading of 59% was obtained.  The resin was capped with 0.22 mL (2 eq to resin-
glutamic acid) acetic anhydride and 0.19 mL (2 eq to resin-glutamic acid) pyridine in 30 
O
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mL of DMF for 30 min. mixing with N2.  Stepwise addition of the next 5 amino acids 
was carried out according to the solid phase method described for compound 1a.  The 
Kaiser test was inconclusive for aminoisobutyric acid free amine, so coupling reactions 
were repeated twice for 10 hr. for resin-bound terminal Aib residues.   
 
The glutamic acid O-Allyl protecting group was removed according to a modified 
procedure.17  A solution of 5.398 g (3 eq) of tetrakis(triphenylphosphine)palladium(0) 
dissolved in 67.5 mL (15 mL/g of resin) 37:2:1 chloroform/acetic acid/N-
methylmorpholine (NMM) was added to the resin and mixed with N2 for 2 hr.  At this 
point, the solution was filtered off and the resin was subjected to a series of rinses:  30 
mL 0.5% DIPEA in DMF, 3x 2 min.; 30 mL 0.5% sodium diethyldithiocarbamate in 
DMF, 3x 10 min.; 30 mL DMF, 1x 2 hr.; 30 mL DMF, 1x 10 min.; 30 mL 0.5% HOBT 
in DMF, 3x 5 min.; 30 mL DMF, 3x 1 min.; 30 mL MeOH, 3x 1 min.; 30 mL EtOH, 1x 1 
min.  The deprotection reaction was repeated and the resin was subjected to similar 
rinses.   
 
2.3.11  Synthesis of 4b 
 
The resin was swelled in 30 mL DMF mixing with N2 for 30 min. to prepare for on-resin 
cyclization.  2.024 g (2.5 eq) PyBOP, 0.526 g (2.5 eq) HOBT, and 1.4 mL (5 eq) DIPEA 
dissolved in 5 mL DMF was added to the resin.  The volume was increased to 50 mL and 
mixed with N2 for 18.5 hr.  The resin was subjected to the normal solid phase rinses and 
vacuum dried.  The Kaiser test was weakly positive, indicating incomplete cyclization, so 
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the cyclization reaction was repeated for 23 hr.  Again, the Kaiser test was weakly 
positive, so the reaction was repeated a third time for 6 hr.  The resin was then rinsed and 
vacuum dried.   
 
The peptide was cleaved from the resin with 30 mL of TFA/H20/TIS 95/2.5/2.5 over 2.5 
hr. by mixing with N2.  The peptide solution was removed by aspiration and concentrated 
down to a few mL’s.  A white solid precipitated out with the addition of cold ether and 
was collected by centrifugation.  The solid was dissolved in 1 mL MeOH.  Added H2O 
precipitated a white solid and the yellow solution was decanted off to give 60 mg (5% 
yield) of a white solid.  ESI MS m/z (%) calcd. for C36H56N7O10 (M+H+) 746.4 found 
746.2 (4), calcd. M-(Z)+H+ 612.4 found 611.9 (100).   
 
2.3.12  Synthesis of 5a 
 
Solid phase synthesis was carried out on 5.228 g D-Ala-Wang resin (0.72 mmol/g 
loading) for the amino acid sequence (D-Ala)—(L-Glu(OBzl))—(D-Leu)—(Aib)—(L-
Lys(Z))—(Aib) as described for compound 1a.  The Kaiser test was inconclusive for 
aminoisobutyric acid free amine so the coupling reaction of the resin-bound terminal Aib 
residue with Fmoc-Lys(Z) was repeated twice for 20 hr. each time.   
 
The peptide was cleaved from the resin with 30 mL of TFA/H20/TIS 95/2.5/2.5 over 1.5 
hr. by mixing with N2.  The peptide solution was removed by aspiration and concentrated 
down to a few mL’s.  The residue was purified by flash column chromatography (19:1 
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DCM:MeOH then 6.1:1 DCM:MeOH) to give 650 mg of a white solid.  Column 
chromatography (2.6:1 DCM:MeOH) was used to purify additional fractions recovered 
from the second flash column to give an additional 330 mg for a total of 980 mg (31% 
yield) of linear peptide.  Rf .30 (3:1 DCM/MeOH);  1H-NMR (400 MHz, MeOD), δ 0.58-
1.66 (m, 37H), 1.81-1.95 (m, 2H), 2.16-2.30 (m, 1H), 2.36-2.45 (m, 1H), 2.82-2.94 (m, 
2H), 3.12 (s, 2H), 3.80-4.06 (m, 4H), 4.75-4.89 (m, 4H), 6.99-7.16 (m, 10H, Ar);  13C-
NMR (100 MHz, MeOD), δ 19.3, 21.8, 23.9, 23.9, 24.1 (CH3), 24.4 (CH2), 26.0 (CH3), 
26.9 (CH), 27.8 (CH3), 28.0, 31.1, 32.2, 32.3, 40.7, 41.8 (CH2), 52.2, 54.6, 55.1, 56.4 
(CH), 58.3, 58.4 (C), 67.6, 67.8 (CH2), 129.2, 129.4, 129.5, 129.9 (CH, Ar), 138.0, 138.8 
(C, Ar), 159.4, 173.4, 174.6, 174.7, 174.8, 176.3, 177.6, 180.2 (C=O).  ESI MS m/z (%) 
calcd. for C43H63N7O11 (M+H+) 854.5 found 854.3 (100), calcd. M+Na+ 876.5 found 
876.3 (33), calcd. M+K+ 892.5 found 892.3 (23). 
 
2.3.13  Synthesis of 5b 
 
800 mg (0.937 mmol) of linear peptide 5a was dissolved in 400 mL DMF and stirred at 0 
˚C.  0.464 g (1.3 eq) HATU, 0.166 g (1.3 eq) HOAT, and 2.4 mL (10 eq) DIPEA in 5 mL 
of DMF was added and the solution was stirred for 4 hr. at which point the DMF was 
removed in vacuo, 45 ˚C.  The residue was taken up in EtOAc and the insoluble white 
precipitate was removed by filtration.  The organic solution was extracted 3x with 30 mL 
10% citric acid, 3x with 30 mL saturated NaHCO3, and dried over Na2SO4.  The solution 
was purified by flash column chromatography (EtOAc) to give 450 mg (57% yield) of a 
white solid.  Rf .47 (EtOAc);  1H-NMR (400 MHz, CDCl3), δ 0.79-0.98 (m, 6H), 1.09-
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2.49 (m, 29H), 2.93-3.36 (m, 2H), 3.73 (t, J = 6.7 Hz, 1H), 4.03-4.21 (m, 1H), 4.41-4.58 
(m, 1H), 4.79-4.94 (m, 1H), 4.98-5.18 (m, 4H), 5.62 (t, J = 5.6 Hz, 1H), 6.17 (s, 1H), 
6.35-6.57 (m, 1H), 6.97-7.20 (m, 2H), 7.21-7.44 (m, 10H, Ar), 7.61 (s, 1H);  13C-NMR 
(100 MHz, CDCl3), δ 16.5, 21.4, 21.4 (CH3), 21.8, 22.5 (CH2), 22.9, 23.4, 23.8 (CH3), 
24.8 (CH), 26.0, 27.9 (CH2), 27.9 (CH3), 30.3, 38.8, 39.5 (CH2), 50.4, 51.4, 51.5, 53.2 
(CH), 56.9, 57.4 (C), 66.4, 66.7 (CH2), 128.5, 128.6, 128.8, 128.9, 129.1 (CH, Ar), 136.2, 
136.9 (C, Ar), 156.8, 172.2, 172.9, 173.5, 174.0, 174.6, 175.9, 176.5 (C=O).  ESI MS m/z 
(%)  calcd. for C43H62N7O10 (M+H+) 836.4 found 836.2 (6), calcd. M+Na+ 858.4 found 
858.2 (100). 
 
2.3.14  Synthesis of 5c 
 
400 mg (0.478 mmol) of 5b was dissolved in 100 mL of 1:1 DCM:MeOH.  The benzyl 
protecting groups on the glutamic acid and lysine side chains were removed by using 0.2 
g of Pd activated carbon (10 wt%) and H2 at atmospheric pressure while stirring the 
solution for 1.5 hr.  The spent catalyst was removed by filtration and the solution was 
concentrated completely in vacuo, 40 ˚C, to give 305 mg (105% yield) of a white solid.  
1H and 13C-NMR spectra in MeOD confirmed complete loss of benzyl protecting groups.  
The peptide was used without further purification or characterization.   
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2.3.15  Synthesis of 5d 
 
305 mg (0.498 mmol) of 5c was dissolved in 150 mL of DMF and stirred at 0 ˚C.  0.246 
g (1.3 eq) HATU, 0.088 g (1.3 eq) HOAT, and 0.87 mL (10 eq) DIPEA dissolved in 5 
mL of DMF was added to the peptide solution for 4 hr. at which point the DMF was 
removed in vacuo, 45 ˚C.  The residue was taken up in EtOAc and the insoluble white 
precipitate was removed by centrifugation.  The organic solution was extracted 3x with 
30 mL of 10% citric acid and 3x with 30 mL of saturated NaHCO3 and dried with 
Na2SO4.  The solution was concentrated completely and dried in vacuo to give 5 mg of a 
white solid.  Characterization by ESI MS was inconclusive.   
 
2.3.16  Synthesis of 6a 
 
Solid phase synthesis was carried out on 5.642 g D-Ala-Wang resin (0.72 mmol/g 
loading) for the amino acid sequence (D-Ala)—(L-Glu(OBzl))—(D-Leu)—(Aib)—(L-
Lys(Z))—(D-Leu) as described for compound 5a.   
 
The peptide was cleaved from the resin in two consecutive reactions of 30 mL of 
TFA/H20/TIS 95/2.5/2.5 mixed with N2 for 30 min. each.  The peptide solutions were 
removed by aspiration, combined, and concentrated to a few mL’s.  The residue was 
purified by column chromatography (4.6:1 DCM:MeOH) and then flash column 
chromatography (19:1 DCM:MeOH) to give 1.40 g (39% yield) of a light yellow solid.  
Rf .30 (4.6:1 DCM/MeOH);  1H-NMR (400 MHz, MeOD), δ 0.61-0.79 (m, 14H), 1.01-
1.35 (m, 16H), 1.37-1.63 (m, 9H), 1.82-1.99 (m, 2H), 2.17-2.30 (m, 1H), 2.32-2.43 (m, 
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1H), 2.89 (t, J = 6.7 Hz, 2H), 3.36-3.48 (m, 2H), 3.67-3.75 (m, 1H), 3.82-3.91 (m, 2H), 
4.01-4.11 (m, 2H), 4.80-4.91 (m, 4H), 7.03-7.16 (m, 10H, Ar);  13C-NMR (100 MHz, 
MeOD), δ 18.9, 21.7, 22.8, 23.5, 24.0, 24.1 (CH3), 24.5 (CH2), 26.0, 26.9 (CH), 27.7 
(CH3), 28.4, 31.0, 32.0, 32.6, 40.6, 41.8, 41.8 (CH2), 52.5, 53.3, 54.4, 54.7, 56.1 (CH), 
58.3 (C), 67.6, 67.8 (CH2), 129.2, 129.4, 129.5, 129.9 (CH, Ar), 138.0, 138.8 (C, Ar), 
159.4, 173.7, 174.9, 174.9, 175.1, 175.9, 177.5, 180.6 (C=O).  ESI MS m/z (%) calcd. for 
C45H67N7O11 (M+H+) 882.5 found 882.6 (15), calcd. M+Na+ 904.5 found 904.6 (30), 
calcd. M+K+ 920.5 found 920.6 (18). 
 
2.3.17  Synthesis of 6b 
 
1.361 g (1.544 mmol) of linear peptide 6a was dissolved in 680 mL DMF and stirred at 0 
˚C.  0.764 g (1.3 eq) HATU, 0.274 g (1.3 eq) HOAT, and 2.7 mL (10 eq) DIPEA 
dissolved in 5 mL of DMF was added and the solution was stirred for 4 hr. at which point 
the DMF was removed in vacuo, 45 ˚C.  The residue was taken up in EtOAc and the 
insoluble white precipitate was removed by filtration.  The organic solution was extracted 
3x with 30 mL 10% citric acid, 3x with 30 mL saturated NaHCO3, and dried over 
Na2SO4.  The solution was purified by flash column chromatography (EtOAc) to give 
600 mg (45% yield) of a white solid.  Rf .40 (EtOAc);  1H-NMR (400 MHz, CDCl3), δ 
0.80-0.99 (m, 12H), 1.19-1.91 (m, 21H), 2.01-2.24 (m, 3H), 2.39-2.48 (m, 2H), 3.10-3.26 
(m, 2H), 3.98-4.15 (m, 2H), 4.18-4.28 (m, 1H), 4.28-4.40 (m, 1H), 4.48-4.58 (m, 1H), 
5.02-5.12 (m, 4H, Ar), 5.44 (t, J = 5.9 Hz, 1H), 6.58 (d, J = 7.8 Hz, 1H), 6.64 (d, J = 8.6 
Hz, 1H), 6.94 (d, J = 5.06 Hz, 1H), 7.06 (s, 1H), 7.28-7.36 (m, 10H, Ar), 7.41-7.46 (m, 
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1H), 7.56 (d, J = 7.1 Hz, 1H);  13C-NMR (100 MHz, CDCl3), δ 17.3, 21.9, 22.1 (CH3), 
22.5 (CH2), 23.6, 23.6 (CH3), 23.7 (CH3), 24.4 (CH2), 25.4, 25.4 (CH), 28.0 (CH3), 28.1, 
29.2, 30.5, 39.7, 40.3, 40.4 (CH2), 51.5, 51.7, 52.4, 52.6, 54.1 (CH), 57.0 (C), 66.9, 67.0 
(CH2), 128.2, 128.3, 128.4, 128.7, 128.7 (CH, Ar), 135.9, 136.8 (C, Ar), 156.8, 172.0, 
172.9, 173.0, 173.0, 173.3, 174.1, 174.7 (C=O).  ESI MS m/z (%) calcd. for 
C45H65N7O10Na (M+Na+) 886.5 found 886.6 (100). 
 
2.3.18  Synthesis of 6c 
 
571 mg (0.661 mmol) of 6b was dissolved in 150 mL of 1:1 DCM:MeOH.  The benzyl 
protecting groups on the glutamic acid and lysine side chains were removed by using 0.2 
g of Pd activated carbon (10 wt%) and H2 at atmospheric pressure while stirring the 
solution for 1.5 hr.  The spent catalyst was removed by filtration and the solution was 
concentrated completely in vacuo, 40 ˚C, to give 400 mg (94% yield) of a white solid.  1H 
and 13C-NMR spectra in MeOD confirmed complete loss of benzyl groups.  The peptide 
was used without further purification or characterization.   
 
2.3.19  Synthesis of 6d 
 
202 mg (0.316 mmol) of 6c was dissolved in 100 mL DMF and stirred at 0 ˚C.  0.156 g 
(1.3 eq) HATU, 0.056 g (1.3 eq) HOAT, and 0.55 mL (10 eq) DIPEA dissolved in 5 mL 
DMF was added to the peptide solution and stirred for 4 hr. at which point the DMF was 
removed in vacuo, 45 ˚C.  The residue was taken up in EtOAc and the insoluble white 
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precipitate was removed by filtration.  The organic solution was extracted 3x with 30 mL 
10% citric acid, 3x with 30 mL saturated NaHCO3, dried over Na2SO4, and concentrated 
completely to give 26 mg of a whitish yellow solid.   
 
The cyclization reaction and workup described above were repeated on the remaining 190 
mg of 6c to give an additional 33 mg for a total of 60 mg (16% yield) of whitish yellow 
solid.  1H-NMR (400 MHz, MeOD), δ 0.84-1.00 (m, 12H), 1.25-1.89 (m, 24H), 1.99-2.21 
(m, 4H), 4.09-4.42 (m, 5H);  13C-NMR (100 MHz, MeOD), δ 17.4, 22.0, 22.7, 23.8, 23.9 
(CH3), 24.4 (CH2), 24.8, 26.4 (CH3), 26.6, 26.6 (CH), 27.7, 29.0, 31.7, 31.9, 40.2, 41.7, 
41.8 (CH2), 54.3, 54.3, 54.0, 54.0, 52.8 (CH), 58.2 (C), 174.2, 174.5, 174.9, 175.3, 175.4, 
175.6, 176.9 (C=O).  ESI MS m/z (%) calcd. for C30H52N7O7 (M+H+) 622.4 found 622.3 
(100). 
 
2.4 ISE Membrane and Electrode Preparation 
 
This work was performed by Dr. John Benco.  Six membrane cocktails were prepared to 
test 6d.  The specific formulations are as follows:  M1, 69/30/1 wt % of nitrophenyl octyl 
ether (NPOE)/PVC/6d; M2, same as M1 with 10 mol % of potassium tetrakis (4-
chlorophenyl)borate (KtpClPB) to 6d; M3, same as M1 with 50 mol % of KtpClPB to 6d; 
M4, 69/30/1 wt % of dioctyl phthalate (DOP)/PVC/6d; M5, same as M4 with 10 mol % 
of KtpClPB to 6d; M6, same as M4 with 50 mol % of KtpClPB to 6d.  Membrane 
cocktails were prepared as 10 wt % solutions in THF.  The base electrodes were 
constructed in a thick-film planar format using a polymeric internal electrolyte layer as 
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previously reported.8  Two wafers composed of 100 individual electrode elements each 
were used for the sensor construction.  The polymer, methacrylamidopropylmethyl-
ammonium chloride (MAPTAC), for the internal electrolyte was prepared as a 10 wt % 
solution in EtOH, spun on to the planar wafers at 750 rpm for 30 s, and allowed to dry for 
1 h before membrane deposition.  Internal electrolyte thickness was ~3.5 µm.  The wafers 
were then quartered, giving wafers of 25 sensors each.  Membrane cocktails were 
deposited (0.9 mL) onto the wafers and allowed to cure for 24 h before use, giving a 
membrane thickness of ~105 µm.  The planar wafers were singulated by hand, giving 25 
sensors for each formulation. 
 
2.5 ISE Testing 
 
This work was carried out by Dr. John Benco.  The sensors were housed in the 
proprietary flow-through cell used with the Bayer Diagnostics Rapidpoint 400 critical 
care system as previously reported.8  This system uses a saturated Ag/AgCl reference 
cell.  Two flow cells were constructed, which contained 1-2 sensors of each formulation 
for a total of 14 tested sensors.  Each cell was tested individually on the Rapidpoint 
system that maintains a 37˚C temperature for the cell.  The sensors were tested using 
solutions containing NH4Cl (0.5-100 mM), 100 mM Tris buffer (pH 7.2), and 0.05 g/L 
Brij 700.  Selectivity testing was based on the separate solution method (SSM)18, where    
i = j = 0.1 M. 
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2.6 13C-NMR Study of Valinomycin binding Potassium Cations 
 
This study was based on a modified procedure.19  A solution was made by dissolving 20 
mg of commercially available valinomycin in 0.50 mL of 1:1 (v:v) MeOD:CDCl3.  A 
13C-NMR spectrum was recorded after each 10 µL addition of stock solutions of 
potassium thiocyanate in 1:1 (v:v) MeOH:CHCl3.  Table 1 shows the KSCN 
concentrations for each experiment.  13C-NMR spectra were recorded by locking on 
MeOD with 512—9000 scans and the spectra were calibrated with respect to MeOD.   
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Table 1:  13C-NMR experiments of valinomycin with increasing amounts of KSCN 
 
Spectrum KSCN (mmol) Total Volume (mL) [KSCN] (mM) 
1 0.0 0.50 0.0 
2 0.2 0.51 0.4 
3 0.4 0.52 0.8 
4 0.6 0.53 1.1 
5 0.8 0.54 1.5 
6 1.2 0.55 2.2 
7 1.6 0.56 2.9 
8 2.0 0.57 3.5 
9 2.4 0.58 4.1 
10 2.8 0.59 4.7 
11 3.2 0.60 5.3 
12 3.6 0.61 5.9 
13 4.5 0.62 7.3 
14 5.4 0.63 8.6 
15 6.3 0.64 9.8 
16 7.2 0.65 11.1 
17 8.1 0.66 12.3 
18 9.0 0.67 13.4 
19 9.9 0.68 14.6 
20 10.8 0.69 15.7 
21 11.7 0.70 16.7 
22 12.6 0.71 17.7 
23 13.5 0.72 18.8 
24 14.4 0.73 19.7 
25 15.3 0.74 20.7 
26 16.2 0.75 21.6 
27 17.1 0.76 22.5 
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3 Results and Discussion 
 
3.1 Selection of Synthetic Methods 
 
 The decision to utilize a solid phase Fmoc-protection strategy on a Wang resin was 
based on the demonstrated success of that strategy in our working group as well as by 
others.17,20-23 These methods are well understood and give good yields.  The mechanisms 
of Fmoc deprotection and PyBOP/HOBT-mediated amino acid coupling are shown below 
in Figures 11 and 12.  The benzyl protecting groups on the glutamic acid and lysine side 
chains were chosen because the protected residues are available commercially and 
because they are known to be stable to Fmoc deprotection conditions (basic) and resin 
cleavage conditions (acidic). These groups are easily removed by hydrogenation. 
 
 
Figure 11:  Mechanism of Fmoc deprotection 
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Figure 12:  Mechanism of PyBOP/HOBT-mediated coupling reaction 
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The use of the activating agents HATU and HOAT in cyclization of the linear peptide 
was based on the experience of both Ghadiri’s working group24 as well as that of our 
own.  The reaction is carried out in DMF under dilute (2 mg/ mL) conditions in order to 
favor intramolecular cyclization over intermolecular coupling.  The mechanism of 
HATU/HOAT-mediated coupling is very similar to that shown for PyBOP in Figure 12.  
Thionyl chloride was employed for the second cyclization step, based on the success our 
group has had with the reagent in the cyclization of a depsipeptide ammonium 
ionophore.8  
 
3.2 Design and Synthesis 
 
3.2.1.1  Design of 1d 
 
The design of bicyclic peptide target compound 1d has elements that are similar to the 
cyclic depsipeptide ammonium ionophore8 reported recently by our group (shown in 
Figure 7b).  Target 1d is the bicyclic and all-amide equivalent of this depsipeptide, both 
of which are shown in Figure 13.  The stereochemical pattern, L—D—D—L—L—D, of 
both is based on the potassium ionophore valinomycin (L—D—D—L)3 and was 
expected, based on modeling, to prevent formation of helices that would hinder 
cyclization. 
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Molecular modeling of 1d indicated that it may offer enhanced ammonium over 
potassium selectivity compared to nonactin, the industry standard ammonium ionophore.  
Whereas nonactin has a flexible crown-ether backbone that allows wrapping-type 
complexes with both ammonium and potassium ions, bicyclic peptide 1d has a more rigid 
structure that provides the tetrahedral coordination required for complexation of 
ammonium ions, but cannot effectively exhibit the octahedral coordination required for 
complexation of potassium ions.  Figure 14 shows minimized structures of 1d with both 
ammonium and potassium ions.  Ammonium ion sits deeply within the cavity and forms 
at least four hydrogen bonds to 1d.  On the other hand, potassium does not sit as deeply 
within the pocket, indicating less favorable complexation. 
Figure 13:  Depsipeptide ammonium ionophore (left) and target compound 1d (right) 
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To estimate the selectivity of 1d for binding ammonium over potassium ions compared to 
nonactin, docking energies were obtained for the ion/ionophore complex in each case, as 
previously reported.8  The difference in docking energies between ammonium and 
potassium ion for 1d was 12 kcal/mol more negative than that calculated for nonactin.  
While these calculations give relative values only, they indicate qualitatively that 1d may 
show increased ammonium over potassium selectivity compared to nonactin. 
 
3.2.1.2  Attempted Synthesis of 1d 
 
The linear peptide 1a was synthesized and characterized in good (67%) yield.  However, 
1a exhibited poor solubility and was very difficult to dissolve in a variety of solvents, 
including DMSO and DMF.  After the first cyclization reaction to give 1b, the solvent 
extraction process created an emulsion between the DCM and aqueous layers, probably 
due to the limited solubility of the peptide in either phase.  Based on the low yield of 1b 
Figure 14:  Complexation of 1d with ammonium (left) and potassium (right) cations 
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(14 %), the decision was made to start a new synthesis of 1a in order to scale up the 
amount of the intermediate 1b.  In an attempt to increase the yield during the cyclization 
of the second batch of 1a, the reaction was carried out in 500 mL of DMF at 0 ˚C for 4 hr 
in order to favor intramolecular cyclization over intermolecular coupling by decreasing 
the rate of collisions by lowering the temperature.  The product of the second synthesis 
was purified by multiple precipitations from MeOH/ether only, since 1b did not exhibit 
sufficient solubility to purify by column chromatography and we believed much of the 
desired product of the first synthetic attempt was lost during the solvent extraction in the 
emulsion that formed.  Intermediate 1b was never unambiguously characterized due to 
the large amount of impurities present, ultimately caused by the poor solubility that 
prevented the use of effective purification techniques.  The 1H and 13C-NMR spectra 
showed the expected signals for peptide 1b, but clearly contained considerable 
impurities.  The MS showed no 1b, but this can potentially be explained by the poor 
solubility of 1b (Synpep Corp., the contractor who provided the MS analysis, used only 
acetonitrile as a matrix).  The final cyclization with thionyl chloride appeared completely 
unsuccessful, resulting in a brown solid that contained no 1d by MS.  In fact, activation 
of the carboxyl group by acid chloride formation is rarely done by peptide practitioners 
due to its reputation of being “overactivated” and therefore prone to numerous side 
reactions.25 
 
 
 
 44 
3.2.2.1  Design of 2d 
 
The attempted synthesis of target compound 1d highlighted the importance of solubility 
in the synthesis of peptides.  Target compound 2d was designed in an attempt to increase 
solubility of intermediate and final compounds by decreasing aggregation through the 
replacement of bulky valine residues by smaller alanine residues.  Additionally, it was 
realized that the incorporation of D-lysine and L-glutamic acid in target compound 1d 
would result in two different atropoisomers depending on which side of the cyclic peptide 
the second ring is formed.  As shown in Figure 15, one isomer has the bridgehead 
hydrogen on glutamic acid pointing outside the cavity and the bridgehead hydrogen on 
lysine pointing in towards the cavity and the other has the bridgehead hydrogen on 
glutamic acid pointing in towards the cavity and the bridgehead hydrogen on lysine 
pointing outside the cavity.  In an attempt to favor the formation of just one atropoisomer, 
the stereochemistry of the bridgehead residues were both designed as L.  As shown in 
Figure 15, the two possible atropoisomers of 2d can have both of the bridgehead 
hydrogens pointing in toward the central cavity or both pointing out away from the 
central cavity.  Based on the work of Paolillo et al.16, the isomer with both hydrogens 
pointing out away from the central cavity should be favored by steric interactions during 
formation of the second ring.  The stereochemistry assignment, L—L—D—D—L—D, 
was designed to give the two most expensive amino acids, the benzyl protected lysine 
and glutamic acid residues, the naturally occurring L configuration in order to minimize 
overall cost of the synthesis while still retaining the stereochemical pattern seen in 
valinomycin and the previous bicyclic target compound 1d.  Molecular modeling 
calculations to estimate the selectivity of target compound 2d with ammonium and 
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potassium ions gave a difference in docking energies similar to that calculated for target 
compound 1d, indicating that the change in amino acid residues and stereochemistry 
should not significantly affect complexation behavior. 
 
3.2.2.2  Synthesis of 2d 
 
In order to evaluate the most effective cyclization conditions, the preliminary synthesis 
product 2a was divided.  One portion was subjected to cyclization using HATU/HOAT 
activation and the other portion was activated with thionyl chloride.  The product of the 
HATU/HOAT cyclization 2b was characterized by MS and 1H and 13C-NMR, but no 2b 
was visible in the MS of the product of the thionyl chloride reaction.  Acid chlorides of 
benzyloxycarbonyl-protected peptides such as 2a are known to undergo the serious side 
Figure 15:  The two possible atropoisomers of (a) target compound 1d (b) target 
compound 2d 
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reaction of spontaneous decomposition to the corresponding Leuchs anhydride with loss 
of benzyl chloride.25  Both the linear peptide 2a and the monocyclized intermediate 2b 
showed limited solubility.  However, solubility was sufficiently high in acetonitrile/water 
solvent systems to successfully purify 2b through reverse phase column chromatography.  
The success of the HATU/HOAT method in the first cyclization led to the decision to 
employ this method for the final cyclization.  Compound 2d was characterized by MS in 
the crude product mixture and was subsequently purified by a series of precipitations 
from MeOH/ether in which a marked decrease in solubility was observed.  The final 
precipitated 2d was essentially insoluble and therefore it was impossible to characterize 
by MS or NMR or to test its utility as an ammonium ionophore in an ISE sensor format. 
 
3.2.3.1  Design of 3d 
 
Target compound 3d was designed to exhibit increased solubility by preventing the 
intermolecular hydrogen bonding that is generally believed to be responsible for the poor 
solubility of peptides26 such as 2a-2d.  We predicted, based on investigations by Narita26, 
that the replacement of two of the alanine residues in 2d with N-methyl alanine residues 
in 3d would increase solubility by disrupting hydrogen bonding between molecules.  The 
amino acid sequence was designed to prevent cyclization at a hindered N-methylated 
amine.  The stereochemistry was unchanged from bicyclic peptide 2d to bicyclic peptide 
target 3d. 
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3.2.3.2  Attempted Synthesis of 3d 
 
Solid phase synthesis of 3a was complicated by the incorporation of the two N-
methylated residues because the Kaiser test used to monitor deprotection and coupling 
reactions is inconclusive for secondary amines.  The Novabiochem catalog contains a 
method for detecting the free secondary amine of proline residues called a chloranil test.17 
However, this technique was inconclusive, usually giving orange or brown resin beads, 
when a blue color is indicative of a positive test, in both the presence and absence of 
secondary amine.  For this reason, the extent of coupling was instead estimated by 
cleaving the Fmoc protecting group from a known mass of resin (20 mg) in a 100 mL 
solution of 20% piperidine in DMF and monitoring the UV absorption at 290 nm.  Since 
the extinction coefficient of the Fmoc group is known at this wavelength to be 4950      
M-1cm-1, the UV absorption of the free Fmoc moiety can be used to calculate the 
concentration of the Fmoc group in solution, which can be related to the amount of 
peptide on the known mass of resin.  However, this technique has limited sensitivity.  The 
MS of the crude mixture after the resin cleavage reaction showed that the linear peptide 
3a was not present, but various deletion peptides were present.  This was strong evidence 
that N-terminal coupling reactions of the N-methylated residues were not effective.   
 
3.2.4.1  Design of 4d 
 
Like target compound 3d, 4d was designed to have increased solubility by preventing 
intermolecular hydrogen bonding.  However, due to the limited success of coupling 
reactions involving N-methylated residues in the synthesis of 3d, the decision was made 
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to incorporate two aminoisobutyric acid residues, which are also known to increase 
solubility by disrupting β-sheet formation26, instead of the N-methylated alanine residues.  
Additionally, we replaced one alanine residue with a leucine residue in an attempt to 
increase the solubility of the peptides by increasing their lipophilicity.   
 
The synthetic strategy for target 4d was developed after a literature search of on-resin 
cyclization methods.27-37 On-resin cyclization methods are desirable because, in theory, 
intermolecular reactions to form polymers are impossible and therefore yields of the 
intramolecular reaction should be increased dramatically compared to solution-phase 
cyclization reactions.  In addition, this strategy would eliminate one step from the 
synthesis.  The method involves anchoring the side chain of glutamic acid to the resin and 
building the linear peptide using standard solid phase techniques using an allyl protecting 
group on the carboxy terminus during chain elongation. This is followed by solution-
phase deprotection of the allyl protecting group prior to on-resin head-to-tail peptide 
cyclization.37  The allyl-protecting group strategy was chosen over other on-resin 
cyclization methods because it required the smallest overall change in strategy.  This 
synthetic scheme still allowed the use of Fmoc protecting groups on the Wang resin and 
benzyl protection for the lysine residue.   
 
3.2.4.2  Attempted synthesis of 4d 
 
The allyl-protecting group on-resin cyclization method gave only 5% yield of crude 
peptide 4b based on an estimated resin loading of 59%.  This is too low for a practical 
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synthesis of 4d.  In addition, MS showed that ~97% of the crude peptide 4b had been 
deprotected (benzyloxycarbonyl protecting group) at the lysine residue leading to the 
conclusion that the benzyl group was removed during the allyl deprotection reaction.  
Since deprotection occurred prior to the cyclization reaction, the deprotected and 
monocyclized peptide formed was most likely a mixture of head-to-tail cyclized and 
head-to-side chain cyclized products since both the N-terminus and the lysine side chain 
amine were available for participation in the cyclization reaction.   
 
3.2.5.1  Design of 5d 
 
Based on the low yield (5% to resin loading) obtained by this on-resin cyclization 
method, the decision was made to return to our previous synthetic strategy of solid phase 
synthesis to produce the linear peptide followed by two solution-phase cyclization 
reactions.  Target compound 5d is the analogue of 4d produced by this synthetic strategy.  
The amino acid sequence was reversed in order to make the solid phase synthesis easier 
by starting with an alanine residue, which is commercially available preloaded on the 
resin.   
 
3.2.5.2  Attempted synthesis of 5d 
 
The first attempt to make 5a via solid phase synthesis resulted in a low yield of an oil. 
This oil was found to contain primarily 5a that had been deprotected (the 
benzyloxycarbonyl protecting group had been lost from the lysine side chain according to 
 50 
the MS).   We suspected that the benzyloxycarbonyl protecting group was lost during the 
6 hr. cleavage reaction.  The work of Erickson et al. confirmed that benzyloxycarbonyl 
protecting groups are approximately 40 to 60 times less stable than benzyl ester 
protecting groups, and that they are removed under the acidic conditions (95% TFA) of 
the cleavage reaction.38  They observed 0.5% deprotection of Lys(Z) after 20 min. 
exposure to 50% TFA in CH2Cl2.  In the second solid phase synthesis of 5a, the cleavage 
reaction time was shortened to 1.5 hr. and repeated twice in order to test which reaction 
time produced optimum yields of the linear peptide.  MS of the two cleavage fractions 
showed a good yield of 5a in the first fraction, but essentially none in the second 
cleavage fraction.  This supported the conclusion that longer cleavage times lowered the 
yield of linear peptide 5a through loss of the benzyloxycarbonyl protecting group.   
 
Both the linear peptide 5a and the monocyclized intermediate 5b exhibited dramatically 
increased solubility in organic solvents compared to intermediates 1a, 2a, 1b, and 2b.  
The linear peptide 5a was completely soluble in pure DCM, despite the free acid and free 
amine functions that may be expected to prevent solubility in such a nonpolar solvent.  
The great solubility of the intermediates 5a and 5b made purification by column 
chromatography highly successful.   
 
The final cyclization reaction and subsequent work-up were performed exactly the same 
as the first cyclization reaction, but gave only 5 mg of a white solid after the solvent 
extraction.  Characterization by MS was inconclusive, since only very low intensity 
signals of the correct mass were observed.   
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3.2.6.1  Design of 6d 
 
After study structures generated by molecular modeling and physical models of target 
peptide 5d, we concluded that the bulky aminoisubutyric acid residues were causing the 
ring to be too rigid to allow for the second cyclization to occur.  Specifically, we 
hypothesized that the methyl groups on the aminoisobutyric acid residue between the 
alanine and lysine residues were initiating an unfavorable steric interaction with the 
alanine carbonyl group as the lysine and glutamic acid side chains began to come 
together to form the second ring.   
 
Target bicyclic peptide 6d was designed on the basis of this hypothesis. The interfering 
aminoisobutyric acid residue was replaced by a lipophilic leucine residue for the purpose 
of decreasing steric hindrance while attempting to retain the good solubility observed in 
the intermediates of 5d.    Both computer and physical models led us to believe that a D 
configuration for the alanine and leucine residues would be most favorable for promoting 
the second cyclization reaction through steric interactions forcing the L-glutamic acid and 
L-lysine side chains onto the same side of the ring. 
 
3.2.6.2  Synthesis of 6d 
 
Intermediates 6a and 6b were synthesized and purified using the same methods that 
proved successful for the second synthesis of 5a and 5b.  Both intermediates also 
exhibited the good solubility seen in 5a and 5b.  In this case, the second cyclization 
reaction was successful in producing bicyclic peptide 6d in 16% yield, lending support to 
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our hypothesis of harmful steric interactions caused by the aminoisobutyric acid residue 
preventing cyclization of 5c. 
 
Multiple precipitations were performed on 6d from THF/ether, DCM/hexane, and 
MeOH/ether/hexane solvent systems in attempts to purify the bicyclic peptide 
(purification by chromatography was not possible because 6d was not visible on TLC 
plates by UV absorption, iodine, or p-anisaldehyde visualization methods).  
Unfortunately, none of these precipitations purified the bicyclic peptide based on 1H and 
13C-NMR (6d seemed partially soluble in all of the tried solvent systems). 
 
3.3 Sensor Fabrication and Testing 
 
Bicyclic peptide 6d was incorporated into a planar ISE structure employing a polymeric 
solid contact material and tested in a commercially available point-of-care clinical 
diagnostic system, as previously reported.8  Six membrane formulations were tested in 
order to determine which environment would yield the best potentiometric response.  
Each sensor membrane consisted of plasticized PVC.  Formulations differed as to the 
type of plasticizer used (NPOE or DOP) and the amount of the lipophilic salt KtpClPB 
present (0, 10, or 50 mol% to 6d).   
 
Figures 16 and 17 show the potentiometric responses of the six membrane formulations 
to increasing concentrations of aqueous NH4Cl.  The membrane containing the plasticizer 
NPOE with 50 mol% KtpClPB to 6d exhibited the largest potential increases with 
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increasing ammonium concentration (highest slope (60.7 mV/dec), closest to the ideal 
Nernstian response (see Table 2)).  The membranes containing the plasticizer NPOE in 
the absence of KtpClPB and all formulations containing the plasticizer DOP exhibited 
sub Nernstian behavior.   
 
Figure 16:  Potentiometric responses of planar ISEs to NH4+ (10-4 – 10-1 M) for 
membranes 1-3 based on 6d 
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In the case of membrane formulations utilizing NPOE (M1-M3), it can be seen that as the 
mole ratio of lipophilic salt to 6d increases there is a corresponding increase in the slope 
of the sensors as a function of ammonium concentration.  In particular, it is observed that 
in the absence of lipophilic salt (i.e. formulation M1) the sensors essentially exhibit no 
response to ammonium ions.  This general trend is also observed in the case of the 
membrane formulations utilizing DOP (M4-M6).  These results suggest that the response 
of the sensors is not determined by the ionophore (and is therefore independent of the 
ionophore), but rather is a function of the lipophilic salt concentration. 
 
Figure 17:  Potentiometric responses of planar ISEs to NH4+ (10-4 – 10-1 M) for 
membranes 4-6 based on 6d 
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Table 2 shows the results of selectivity studies that were carried out on the six membrane 
formulations using the separate solution method.  M3, the formulation showing the best 
response for ammonium cation, was in fact the most selective for potassium, followed by 
ammonium, sodium, calcium, magnesium, and lithium cations (K+ > NH4+ > Na+ > Ca2+ 
> Mg2+ > Li+).  The other membrane formulations (with the exception of M1, which was 
least selective for ammonium) showed a similar selectivity pattern.  This sequence of 
cation selectivity shows a good correlation to the Hofmeister series (K+ > NH4+ > Na+ > 
Li+ ~ Ca2+ > Mg2+), which has been observed for ISE membranes incorporating the 
plasticizers NPOE and DOP without any ionophore component.18 The sequence of cation 
selectivities (in the absence of ionophore) is determined by the difference between the 
standard free energies of solvation for the ions in the aqueous and organic phases 
respectively.  Taken alone, the results of the selectivity studies indicate that 6d is more 
selective for potassium ions than for ammonium ions.  However, the potentiometric 
results (as shown in Figures 16 and 17) in combination with the selectivity data provide 
evidence that the potentiometric response of the sensors is independent of the ionophore 
and is instead dependent only on the lipophilic salt likely acting as a non-specific ion 
exchanger.  In light of these results, we suggest that the ionophore is not soluble in the 
membrane phase and is therefore incapable of forming complexes with ions.  This 
suggestion is supported by the low solubility of 6d observed in nonpolar solvents such as 
THF and CHCl3.  These solvents have dielectric constants (ε = 7.6 and 4.8 respectively) 
on the same order of NPOE and DOP plasticized PVC membranes (εmem = 14 and 4.8 
respectively)18 and thus model the polymeric matrix of the membrane phase.  In addition, 
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1H-NMR spectra of 6d in CDCl3 and THF-d8 show broad structureless resonances for all 
peaks, indicative of poor solubility. 
 
Table 2:  Selectivity of 6d for Ammonium over Other Cations 
 
3.4 13C-NMR Study of Valinomycin binding Potassium Cations 
 
Due to the apparent lack of solubility of 6d in the ISE membranes, the decision was made 
to employ solution NMR methods in an attempt to evaluate the selectivity of 6d for 
ammonium over other interfering cations.  Selectivities of ionophores in solution are 
calculated from the ratios of the equilibrium dissociation constants for the metal-ligand 
complexes of the various cations.  The dissociation constant (Kd) of a ligand with a given 
metal cation may be calculated by fitting a sigmoidal plot of experimental data to 
Equation 2 to give Kd: 
 Selectivity coefficients, log POT jNHK ,4+  
 
Membranea Li+ Na+ K+ Ca2+ Mg2+ Slopeb 
       
M1 0.5 0.7 1.2 0.6 0.4 6.8 
M2 -1.8 -1.2 -0.3 -1.6 -1.7 48.6 
M3 -2.3 -1.0 0.1 -1.5 -1.8 60.7 
M4 -1.0 -0.7 0.0 -0.9 -1.1 20.7 
M5 -0.7 -0.3 0.3 -0.8 -1.0 37.5 
M6 -1.4 -0.8 0.0 -2.6 -2.6 45.8 
Nonactind -3.54 -2.44 -1.04 -3.87 -4.07 59.3c 
       
a M1, 69/30/1 wt % of NPOE/PVC/6d; M2, same as M1 with 10 mol % of KtpClPB to 
6d; M3, same as M1 with 50 mol % of KtpClPB to 6d; M4, 69/30/1 wt % of 
DOP/PVC/6d; M5, same as M4 with 10 mol % of KtpClPB to 6d; M6, same as M4 with 
50 mol % of KtpClPB to 6d.  bDetermined between 10-3 and 10-1 M cation at 37ºC.  cAt 
25ºC.  dData for nonactin taken from references indicated. 
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x
xy +
Β=
d
max
K
   (2) 
 
Here, x is the concentration of free ligand, y is the complex fraction, and Bmax is the 
maximum number of binding sites.  Based on molecular modeling, it appears that the 
carbonyl groups of 6d are primarily responsible for forming the hydrogen bonds to 
ammonium cations (or ion-dipole interactions with interfering cations), although some 
amide nitrogen atoms also seem to contribute.  The carbonyl groups should give the best 
measure of complexation because they should undergo the greatest change in electronic 
environment upon cation binding.  Carbonyl participation in hydrogen bonding (or ion-
dipole interactions) causes an increase in electron density toward the oxygen atom with a 
concurrent decrease in electron density away from the carbon atom.  For this reason, the 
deshielded carbon atoms of the carbonyls of 6d should show a downfield shift in the 13C-
NMR spectra upon complexation.  Comparison of the integration of the free versus 
complexed carbonyl signals in the 13C-NMR spectra of 6d should allow determination of 
the extent of complexation occurring in a given solution.   
 
In order to establish test conditions and validate the method, a control study of 
valinomycin was performed.  Valinomycin (shown in Figure 7a) is the standard 
potassium ionophore used commercially in biosensors.  A cyclic depsipeptide consisting 
of alternating amide and ester linkages (12 total), valinomycin preorganizes through 
hydrogen bonding of its amide carbonyl groups to form a pocket with its six ester 
carbonyl oxygens available for electrostatic stabilization of potassium ions through 
octahedral-type complexation.  Due to the symmetry of the molecule, free (uncomplexed) 
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valinomycin only shows four carbonyl signals, two ester and two amide, in its 13C-NMR 
spectrum.  The ion-dipole interaction which takes place upon binding of potassium by 
valinomycin induces a shift of electron density on the carbonyl bonds towards the oxygen 
atoms resulting in an observed downfield shift of these signals.19  
 
The decision was made to employ a 1:1 CDCl3:MeOD solvent system in the NMR study 
since cation complexation is most favorable in nonpolar solvents, but the polar solvent 
MeOD is necessary for solubility of 6d.  20 mg of valinomycin was dissolved in 0.50 mL 
of 1:1 CDCl3:MeOD (3.6 mM solution) and the initial spectrum was attained.  Spectra 
were performed on the same solution after every 10 µL addition of stock solutions of 
KSCN in 1:1 CHCl3:MeOH (with an increasing number of scans as the solvent peaks 
grew in intensity).  The downfield (complexed) carbonyl signals began to appear at a 
1:1.6 mole ratio of valinomycin to KSCN and gradually increased in comparison to the 
free valinomycin signals (see Figure 18) until the free signals were indistinguishable 
from the noise (complexation ~100%) at a 1:5.75 mole ratio of valinomycin to KSCN.   
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Figure 18:  13C-NMR carbonyl signals of valinomycin as a function of [KSCN] 
0.0 mM KSCN 
8.6 mM KSCN 
12.3 mM KSCN 
16.7 mM KSCN 
.    
20.7 mM KSCN 
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The extent of complexation of each solution was estimated from comparison of the 
integration (by peak height) of the farthest upfield (~171 ppm) and farthest downfield 
(~177 ppm) signals, which were selected because no splitting of these peaks was 
observed.  The slight signal splitting observed is probably due to the loss of symmetry 
(and therefore signal equivalence) caused by the change in conformation upon binding 
the potassium cation.  The plot of complexation versus KSCN concentration is shown in 
Figure 19.  This data was imported into SigmaPlot 8.02 and the program settings for 
simple ligand binding for one site saturation were used to fit the curve to Equation 2, 
resulting in Kd = 10-2 M.  This is two orders of magnitude higher than the known value 
for the binding of potassium by valinomycin in MeOH (Kd = 10-4 M).18  However, the 
difference could be due to water contamination of the sample (Kd = 0.4 M in H2O)18, 
which could increase the dissociation constant significantly. 
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Figure 19:  Valinomycin-potassium complex as a function of potassium concentration 
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4 Conclusions 
 
A series of bicyclic peptides have been designed for complexation of ammonium cations 
through hydrogen bonding.  Molecular modeling suggested these compounds could 
exhibit better ammonium over potassium cation selectivity than nonactin, the industry 
standard ammonium ionophore, in an ISE sensor format by exhibiting the tetrahedral 
coordination geometry required for ammonium binding, but not the octahedral 
coordination geometry required for potassium binding.   
 
Bicyclic peptide 2d was synthesized, but lacked the solubility necessary for 
characterization or evaluation in an ISE sensor.  We were successful in enhancing 
solubility of the peptide intermediates of 5d in organic solvents through the incorporation 
of two aminoisobutyric acid residues.  However, the second cyclization reaction was 
unsuccessful, presumably due to an unfavorable steric interaction between one of the 
aminoisobutyric acid residues and the carbonyl group of the neighboring alanine residue. 
Replacement of this aminoisobutyric acid residue in 5d with a leucine residue led to the 
successful synthesis and characterization of bicyclic peptide 6d.  6d was incorporated 
into an ISE sensor and tested as an ammonium ionophore, but lacked solubility in the ISE 
membrane.   
 
Future work will involve a solution 13C-NMR study of ammonium, potassium, and 
sodium ion binding with 6d.  Preliminary results of a control 13C-NMR potassium-
binding study of valinomycin suggest this method should be successful in evaluating 
selectivity of 6d for ammonium over interfering cations. 
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Appendix:  1H, 13C, and DEPT135 NMR Spectra and ESI MS 
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